Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,866 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Healthy
Interventions: PF-06650833, Ethinyl estradiol (EE) and levonogestrel (LN); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Restless Legs Syndrome
Interventions: Rotigotine; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 9 more

Conditions: Smoking, Smoking Cessation, Motivation, Nicotine Dependence
Interventions: Nicotine Patch, Nicotine Gum, Motivational Interviewing, Smoking Reduction, No Intervention, Nicotine Patch + Nicotine Gum; Drug · Behavioral · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Primary Immune Deficiency
Interventions: Human Normal Immunoglobulin for Subcutaneous Administration; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 2 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 13
States / cities: Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 9 more

Conditions: Dense Deposit Disease, Membranoproliferative Glomerulonephritis
Interventions: Eculizumab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: New York, New York

Conditions: Palliative Care, Chronic Disease
Interventions: Reiki; Other
Lead sponsor: Ohio State University; Other
Eligibility: 10 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Akron, Ohio • Columbus, Ohio

Conditions: Schizophrenia
Interventions: Ondansetron followed by placebo, Placebo followed by Ondansetron; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Substance Use Disorders, Pain
Interventions: SBIRT-PM; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Stage 2 Diastolic Hypertension
Interventions: nebivolol and lisinopril (free combination), nebivolol monotherapy, lisinopril monotherapy, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 664 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 89
States / cities: Scottsdale, Arizona • Tempe, Arizona • Tucson, Arizona + 69 more

Conditions: Autism Spectrum Disorder (ASD)
Interventions: Omega-3 Fatty Acid; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Weight Loss, Pediatric Obesity
Interventions: iAmHealthy Parents First, iAmHealthy; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 6 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: AL Amyloidosis
Interventions: CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Stanford, California • Detroit, Michigan • Cleveland, Ohio

Conditions: Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
Interventions: Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin, Rituximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 26
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 21 more

Conditions: End Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Kidney Disease
Interventions: Moda-flx Hemodialysis System; Device
Lead sponsor: Diality Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ontario, California

Conditions: Hip Fractures, Lower Extremity Fracture, Lung Transplant
Interventions: Patient Mobility; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Narcolepsy Type 1 (NT1)
Interventions: VX-433, Placebo, Midazolam, Bupropion; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Narcolepsy, Narcolepsy Type 1, Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy, Nightmare, Nightmare Disorder With Associated Other Sleep Disorder
Interventions: Imagery Rehearsal Therapy (IRT); Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Uveal Melanoma
Interventions: Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 19
States / cities: Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 15 more

Conditions: Urinary Bladder Neoplasms
Interventions: AGEN1884, AGEN2034, Cisplatin, Gemcitabine; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions: ASTX727, Dacogen; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 39
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more

Conditions: Cardiovascular Diseases
Interventions: Low polyphenol concentration extra virgin olive oil (EVOO), High polyphenol concentration extra virgin olive oil (EVOO); Dietary Supplement
Lead sponsor: Ralph Hamill; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Brunswick, Maine • Rockport, Maine • Scarborough, Maine

Conditions: Peripheral T Cell Lymphoma
Interventions: Nivolumab, Etoposide, Prednisolone, Oncovin, Cyclophosphamide, Hydroxydaunorubicin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Duarte, California • Aurora, Colorado • Philadelphia, Pennsylvania

Conditions: Recurrent Respiratory Papillomatosis
Interventions: Avastin® (bevacizumab), Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

Identifying Treatments to Motivate Smokers to Quit

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

Teaching Parents Reiki for Their Adolescents Receiving Palliative Care

Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia

Pilot of Pragmatic SBIRT Study

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders

iAmHealthy Parents First: A Televideo Parent and Child Obesity Program for Rural Families

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings

Can Mobility Technicians Provide Value to Hospitalized Patients?

A Phase 1, First-in-human Study of VX-433

Decreasing Nightmares in Adults With Narcolepsy

Tebentafusp-tebn With LDT in Metastatic UM

Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

A Multicenter Pilot Study to Evaluate the Effect of EVOO on Lipid Parameters

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)